The vessels were larger at end‐point in the tumours injected with ELTD1‐EVs compared to the controls and this may be mediated by the pro‐angiogenic activity of the ELTD1‐enriched EVs and explain the enhanced proliferation. Here, ADGRL4 is linked to neoplasm.